Jamie E. Chaft

31.7k total citations · 11 hit papers
175 papers, 10.2k citations indexed

About

Jamie E. Chaft is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jamie E. Chaft has authored 175 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Pulmonary and Respiratory Medicine, 111 papers in Oncology and 30 papers in Cancer Research. Recurrent topics in Jamie E. Chaft's work include Lung Cancer Treatments and Mutations (119 papers), Lung Cancer Diagnosis and Treatment (76 papers) and Cancer Immunotherapy and Biomarkers (63 papers). Jamie E. Chaft is often cited by papers focused on Lung Cancer Treatments and Mutations (119 papers), Lung Cancer Diagnosis and Treatment (76 papers) and Cancer Immunotherapy and Biomarkers (63 papers). Jamie E. Chaft collaborates with scholars based in United States, Japan and Spain. Jamie E. Chaft's co-authors include Mark G. Kris, Matthew D. Hellmann, Gregory J. Riely, Marc Ladanyi, Maria E. Arcila, Camelia S. Sima, Valerie W. Rusch, Andrew J. Plodkowski, Maureen F. Zakowski and William D. Travis and has published in prestigious journals such as New England Journal of Medicine, Cell and Nature Communications.

In The Last Decade

Jamie E. Chaft

165 papers receiving 10.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

2018 712 citations Kathryn C. Arbour, Niamh M. Long et al. Journal of Clinical Oncology profile →
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

2018 631 citations Matthew D. Hellmann, Darragh Halpenny et al. profile →
Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis

2014 601 citations Jamie E. Chaft, Mark G. Kris et al. profile →
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer

2016 486 citations Ai Ni, Jamie E. Chaft et al. profile →
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

2016 481 citations Jamie E. Chaft et al. profile →
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. profile →
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

2014 416 citations Matthew D. Hellmann, Jamie E. Chaft et al. profile →
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas

2012 366 citations Maria E. Arcila, Jamie E. Chaft et al. Clinical Cancer Research profile →
EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

2013 348 citations Maria E. Arcila, Khédoudja Nafa et al. Molecular Cancer Therapeutics profile →
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

2017 235 citations Mark G. Kris, Jamie E. Chaft et al. Journal of Clinical Oncology profile →
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer

2021 222 citations Jamie E. Chaft, Andreas Rimner et al. profile →

Peers

Countries citing papers authored by Jamie E. Chaft

Since Specialization

Citations

This map shows the geographic impact of Jamie E. Chaft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie E. Chaft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie E. Chaft more than expected).

Fields of papers citing papers by Jamie E. Chaft

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamie E. Chaft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie E. Chaft. The network helps show where Jamie E. Chaft may publish in the future.

Co-authorship network of co-authors of Jamie E. Chaft

This figure shows the co-authorship network connecting the top 25 collaborators of Jamie E. Chaft. A scholar is included among the top collaborators of Jamie E. Chaft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamie E. Chaft. Jamie E. Chaft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry 2025 ·Clinical Cancer Research ·(unknown), (unknown), Navin R. Mahadevan, (unknown), (unknown), Paul K. Paik, Jamie E. Chaft, (unknown), Sarina A. Piha‐Paul, Pasi A. Jänne, David A. Barbie, Lynette M. Sholl, Steven G. DuBois, Glenn J. Hanna, Geoffrey I. Shapiro, Christopher A. French, Jia Luo	2
2	Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma 2024 ·JTCVS Open ·(unknown), Cameron N. Fick, Brooke Mastrogiacomo, Kay See Tan, (unknown), (unknown), Gaetano Rocco, Jamie E. Chaft, Puneeth Iyengar, (unknown), Prasad S. Adusumilli, (unknown), James M. Isbell, Matthew J. Bott, Smita Sihag, Daniela Molena, James Huang, David R. Jones	0
3	MA05.10 Presenting Features and Diagnostic Delays of NUT Carcinoma: A Report from the NUT Carcinoma Registry 2024 ·Journal of Thoracic Oncology ·Jia Luo, (unknown), Julie Kim, (unknown), Jean W. Liew, (unknown), Tom Nguyen, Paul K. Paik, Jamie E. Chaft, (unknown), Sarina A. Piha‐Paul, Pasi A. Jänne, David A. Barbie, Lynette M. Sholl, Sydney Dubois, Glenn J. Hanna, Geoffrey I. Shapiro, Charles French	1
4	Exploratory analysis of CTDNA and imaging response in Phase I/II chorus study of canakinumab with chemoradiation and durvalumab for NSCLC 2024 ·(unknown), (unknown), Michael Offin, Daphna Y. Gelblum, Fernando C. Santini, (unknown), Michael Berger, Ronak Shah, Daniel R. Gomez, Jamie E. Chaft	1
5	Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·Marina Chiara Garassino, Heather A. Wakelee, Jonathan Spicer, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Ke‐Neng Chen, (unknown), Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, Delvys Rodríguez‐Abreu, Jamie E. Chaft, Jing Yang, Ashwini Arunachalam, Josephine M. Norquist, Steven M. Keller, Shugeng Gao	2
6	Moving Immunotherapy Into the Treatment of Resectable Non–Small Cell Lung Cancer 2024 ·American Society of Clinical Oncology Educational Book ·Jamie E. Chaft, Rafał Dziadziuszko, Bernardo H. L. Goulart	7
7	Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry. 2024 ·Journal of Clinical Oncology ·Jia Luo, (unknown), (unknown), (unknown), Paul K. Paik, Jamie E. Chaft, (unknown), Sarina A. Piha‐Paul, Pasi A. Jänne, Lynette M. Sholl, Steven G. DuBois, Glenn J. Hanna, Geoffrey I. Shapiro, Christopher A. French	1
8	A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease. 2024 ·Journal of Clinical Oncology ·Helena A. Yu, Monica F. Chen, Angela Bik‐Yu Hui, Noura J. Choudhury, Jake June-Koo Lee, (unknown), Linda S. Ahn, (unknown), Monica Nesselbush, (unknown), Glenn Heller, Kathryn C. Arbour, Fernando C. Santini, Michael Offin, Jamie E. Chaft, Robert J. Young, Gregory J. Riely, Mark G. Kris, Maximilian Diehn, Adrienne Boire	6
9	KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. 2023 ·Journal of Clinical Oncology ·Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Jie He, Shugeng Gao, Ke‐Neng Chen, (unknown), Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, Delvys Rodríguez‐Abreu, Jamie E. Chaft, Silvia Novello, Jing Yang, Steven M. Keller, Ayman Samkari, Jonathan Spicer	11
10	Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Joao V. Alessi, Adam Price, Allison L. Richards, Biagio Ricciuti, Xinan Wang, Arielle Elkrief, Federica Pecci, Alessandro Di Federico, (unknown), Emily S. Lebow, Patricia Mae G. Santos, Maria Thor, Andreas Rimner, Adam J. Schoenfeld, Jamie E. Chaft, Bruce E. Johnson, Daniel R. Gomez, Mark M. Awad, Narek Shaverdian	5
11	Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer 2023 ·Clinical Cancer Research ·Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, (unknown), Janis M. Taube, Valsamo Anagnostou, Kellie N. Smith, Joanne Riemer, Peter B. Illei, Stephen Broderick, David R. Jones, Suzanne L. Topalian, Drew M. Pardoll, Julie R. Brahmer, Jamie E. Chaft, Patrick M. Forde	44
12	The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non–small cell lung cancer 2023 ·Journal of Thoracic and Cardiovascular Surgery ·Biniam Kidane, Matthew J. Bott, Jonathan Spicer, Leah M. Backhus, Jamie E. Chaft, Neel P. Chudgar, Yolonda L. Colson, Thomas A. D’Amico, Elizabeth A. David, Jay Lee, Sara Najmeh, Boris Sepesi, Catherine A. Shu, Jeffrey Yang, Steven Swanson, Brendon M. Stiles	24
13	Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas 2022 ·Nature Communications ·Paul K. Paik, Jia Luo, Ni Ai, (unknown), Linda S. Ahn, Anup Biswas, Courtney Coker, Wanchao Ma, Phillip Wong, Darren J. Buonocore, W. Victoria Lai, Jamie E. Chaft, Swarnali Acharyya, Joan Massagué, Mark G. Kris	13
14	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade 2020 ·Cancer Discovery ·Qu Zhang, Jia Luo, Song Wu, Han Si, Chen Gao, Wenjing Xu, Shaad E. Abdullah, Brandon W. Higgs, Phillip A. Dennis, Michiel S. van der Heijden, Neil H. Segal, Jamie E. Chaft, Todd Hembrough, J. Carl Barrett, Matthew D. Hellmann	221
15	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC 2018 ·Cancer Immunology Research ·Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski, Ai Ni, Mario E. Lacouture, Maya Gambarin‐Gelwan, Olivia Wilkins, Elizabeth Panora, Darragh Halpenny, Niamh M. Long, Mark G. Kris, Charles M. Rudin, Jamie E. Chaft, Matthew D. Hellmann	263
16	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer 2018 ·Journal of Clinical Oncology ·Nathan A. Pennell, Joel W. Neal, Jamie E. Chaft, Christopher G. Azzoli, Pasi A. Jänne, Ramaswamy Govindan, Tracey L. Evans, Daniel B. Costa, Heather A. Wakelee, Rebecca S. Heist, Marc A. Shapiro, Alona Muzikansky, Sudish C. Murthy, Michael Lanuti, Valerie W. Rusch, Mark G. Kris, Lecia V. Sequist	137
17	A Comparison of Trimodality Therapy Versus Definitive Concurrent Chemoradiation in Patients With Stage IIIA Non–small Cell Lung Cancer 2017 ·International Journal of Radiation OncologyBiologyPhysics ·Annemarie F. Shepherd, Jonathan E. Leeman, Aaron T. Wild, Brandon S. Imber, Xin Pei, (unknown), Ellen Yorke, James M. Isbell, Jamie E. Chaft, Daphna Y. Gelblum, Abraham J. Wu, Andreas Rimner	2
18	HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers 2015 ·Journal of Thoracic Oncology ·Bob T. Li, Dara S. Ross, Dara L. Aisner, Jamie E. Chaft, Meier Hsu, Severine Kako, Mark G. Kris, Marileila Varella‐Garcia, Maria E. Arcila	212
19	EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics breakdown → 2013 ·Molecular Cancer Therapeutics ·Maria E. Arcila, Khédoudja Nafa, Jamie E. Chaft, Natasha Rekhtman, Christopher Lau, Boris Reva, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi	348
20	Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling 2011 ·Molecular Cancer Therapeutics ·Jamie E. Chaft, Maria E. Arcila, Paul K. Paik, Christopher Lau, Gregory J. Riely, M. Catherine Pietanza, Maureen F. Zakowski, Valerie W. Rusch, Camelia S. Sima, Marc Ladanyi, Mark G. Kris	162

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact